0000014506 00000 n
0000008770 00000 n
0000004586 00000 n
0000004103 00000 n
Eradication of . has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14)]. PREVACID and PREVACID SoluTab are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults.
0000003554 00000 n
Controlled studies do not extend beyond 12 months PREVACID and PREVACID SoluTab are indicated in adults for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer PREVACID and PREVACID SoluTab are indicated in adults for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. ©2019 GSK group of companies or its licensor. 0000001215 00000 n
0000022879 00000 n
(1... Prevacid (Page 5 of 14) REMEDYREPACK INC. 1 April 2019. 0000015998 00000 n
0000013108 00000 n
0000021993 00000 n
1.3 Maintenance of Healed Duodenal Ulcers . 0000002604 00000 n
PD-Rx Pharmaceuticals, Inc. 19 April 2019. 0000026014 00000 n
PREVACID- lansoprazole capsule, delayed release PD-Rx Pharmaceuticals, Inc. 1 INDICATIONS AND USAGE 1.1 Treatment of Active Duodenal Ulcer. 0000014528 00000 n
Controlled studies did not extend beyond 12 months PREVACID and PREVACID SoluTab are indicated in adults for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent. (see the clarithromycin package insert, MICROBIOLOGY section). Trademarks are owned by or licensed to the GSK group of companies. 0000001847 00000 n
This site is provided for educational and informational purposes only, in accordance with our 0000004564 00000 n
0000001125 00000 n
1.2 Non-Small Cell Lung Cancer. Lansoprazole delayed-release capsules 15 mg / acid reducer • May take 1 to 4 days for full effect • Sodium Free. 0000001450 00000 n
Use aseptic technique. 0000013086 00000 n
PREVACID and PREVACID SoluTab are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer PREVACID or PREVACID SoluTab in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with Please refer to the full prescribing information for amoxicillin and clarithromycin.PREVACID or PREVACID SoluTab in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with Please refer to the full prescribing information for amoxicillin.PREVACID and PREVACID SoluTab are indicated in adults to maintain healing of duodenal ulcers. Reconstitute Cyclophosphamide with 0.9% Sodium Chloride Injection, USP only, using the volumes listed below in Table 1. For Direct Intravenous Injection . 0000002946 00000 n
KEEP THE CARTON AND PACKAGE INSERT… 0000022787 00000 n
%PDF-1.4
%����
0000011662 00000 n
0000006487 00000 n
If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted. 0000010271 00000 n
0000017062 00000 n
If there is a recurrence of erosive esophagitis an additional eight week course of PREVACID or PREVACID SoluTab may be considered PREVACID and PREVACID SoluTab are indicated in adults to maintain healing of EE. 42 CAPSULES. 0000021902 00000 n
Cyclophosphamide is soluble in water, saline and ethanol. THREE 14-DAY COURSES OF TREATMENT.
0000007174 00000 n
0000011640 00000 n
Please refer to the full prescribing information for amoxicillin. 0000004525 00000 n
0000001429 00000 n
0000001656 00000 n
Risk Summary. Cyclophosphamide does not contain any antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions. Distributed by: GSK Consumer Healthcare, Warren, NJ 07059. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. 0000008748 00000 n
8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy. 0000015977 00000 n
PREVACID 24HR. 0000007196 00000 n
Controlled studies did not extend beyond eight weeks PREVACID and PREVACID SoluTab are indicated in adults for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks PREVACID and PREVACID SoluTab are indicated for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for the treatment of heartburn and other symptoms associated with GERD PREVACID and PREVACID SoluTab are indicated for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for healing and symptom relief of all grades of EE.For adults who do not heal with PREVACID or PREVACID SoluTab for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment.
9 0 obj
<<
/Linearized 1
/O 11
/H [ 1215 235 ]
/L 51275
/E 30800
/N 2
/T 50978
>>
endobj
xref
9 39
0000000016 00000 n
0000028691 00000 n
0000003846 00000 n
H. pylori . 0000010249 00000 n
0000022972 00000 n